Follicular lymphoma is a B-cell lymphoma. Specifically, it is the second most common type of non-Hodgkin lymphoma, accounting for nearly 30% of all lymphomas and roughly 6 new cases per 100,000 people per year in the United States. It originates from B-cells found in the germinal centers of lymph nodes, the areas where immune cells normally mature and learn to fight infections.
Where Follicular Lymphoma Fits in the Lymphoma Family
Lymphomas split into two broad categories: Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphomas are further divided by the type of white blood cell involved. B-cell lymphomas arise from B-cells (the immune cells responsible for making antibodies), while T-cell lymphomas arise from T-cells. Follicular lymphoma falls squarely in the B-cell camp. It is classified as a mature B-cell neoplasm, meaning the cancerous cells resemble B-cells that have already gone through early development.
Among B-cell non-Hodgkin lymphomas, follicular lymphoma is the most common slow-growing (indolent) subtype. The only non-Hodgkin lymphoma diagnosed more frequently is diffuse large B-cell lymphoma, which is aggressive and behaves quite differently.
How It Develops From Normal B-Cells
The story of follicular lymphoma starts with a genetic accident. In most cases, a piece of chromosome 14 swaps places with a piece of chromosome 18. This translocation places a gene called BCL2 next to a powerful activator from the immune system’s antibody-producing machinery. The result: B-cells overproduce a protein that blocks their natural self-destruct program. Normal B-cells die off when they’re no longer needed, but these altered cells survive far longer than they should, gradually accumulating in the follicles of lymph nodes.
This initial event actually happens outside the germinal center, but the affected cells eventually home to germinal centers throughout the lymph system. In early stages, the abnormal B-cells are often largely confined to these germinal centers in lymph nodes and other lymphoid tissue, which is why the disease carries the name “follicular.”
Symptoms and How It’s Found
Follicular lymphoma tends to grow slowly, sometimes so slowly it causes no symptoms at all. Many people are diagnosed only after the disease has already spread to multiple parts of the body, simply because it never announced itself with obvious warning signs.
When symptoms do appear, the most common include painless swelling in the neck, armpit, or groin (enlarged lymph nodes), persistent fatigue, unexplained fevers, night sweats, unintentional weight loss, and feeling full quickly after eating. Because these symptoms overlap with many other conditions, a biopsy is needed to confirm the diagnosis.
Confirming the B-Cell Identity
Pathologists confirm follicular lymphoma by examining tissue under a microscope and testing for specific proteins on the cell surface. Because it is a B-cell lymphoma, the cells carry B-cell markers. In studies of lymph node biopsies, CD20 (a protein found on nearly all B-cells) is positive in 100% of cases. CD19, another core B-cell marker, is also universally present. CD10, a marker tied to germinal center origin, shows up in about 86% of cases.
One especially useful diagnostic clue is BCL2. Normal germinal center B-cells do not express BCL2, so when follicle center cells test positive for it (roughly 84% of follicular lymphoma cases), that strongly suggests a cancerous rather than a reactive process. These markers collectively paint a clear picture: follicular lymphoma cells are B-cells, and they carry the molecular fingerprints of the germinal center where they originated.
Grading: Not All Follicular Lymphoma Is the Same
Follicular lymphoma is graded from 1 to 3 based on how the cells look under a microscope. The key factor is how many large, immature-looking cells (called centroblasts) appear in a given field of view. Grade 1 has fewer than 5 per high-power field, grade 2 has 5 to 15, and grade 3 has more than 15. Grade 3 is further split: 3A still has a mix of cell types, while 3B shows solid sheets of these large cells.
Grades 1 and 2 behave indolently, with survival measured in years and sometimes decades. Grade 3B behaves more like an aggressive lymphoma and is typically treated differently. This grading system matters because it directly influences treatment decisions and what you can expect going forward.
Risk of Transformation
One important thing to understand about follicular lymphoma is that it can transform into a more aggressive type of B-cell lymphoma, most commonly diffuse large B-cell lymphoma. In a large population study, about 3.3% of follicular lymphoma patients developed this transformation over a median follow-up of roughly 10 years. The median time from initial diagnosis to transformation was about 4 years.
Early transformation (within the first few years) may represent a biologically different and more aggressive process than late transformation. This is one reason doctors monitor follicular lymphoma patients regularly, even during periods of “watch and wait” when no treatment is being given. New or rapidly growing symptoms, especially in a single area, can prompt a repeat biopsy to check whether transformation has occurred.
Why Its B-Cell Identity Shapes Treatment
The fact that follicular lymphoma is a B-cell lymphoma directly determines how it is treated. The cancerous cells display CD20 on their surface, which makes them a target for therapies designed to latch onto that protein. These treatments work by flagging the lymphoma cells for destruction by the immune system, triggering the cells’ own death signals, or activating immune proteins that punch holes in the cell membrane.
This targeting approach has fundamentally changed outcomes for people with follicular lymphoma. Because the treatment zeroes in on a protein that sits on B-cells specifically, it can attack lymphoma cells throughout the body while leaving most other cell types alone. It is one of the clearest examples in cancer medicine of how knowing the exact cell of origin translates directly into an effective treatment strategy.
For many people with low-grade follicular lymphoma that isn’t causing symptoms, active surveillance (sometimes called “watch and wait”) is a legitimate first approach. Treatment typically begins when the disease starts causing problems, growing more quickly, or affecting organ function. The slow growth rate of most follicular lymphomas means that many patients live with the disease for years, managing it as a chronic condition rather than facing an immediate crisis.